SCHEMBL22344795

SCHEMBL22344795

CCn1nc2c(c1C(O)c1ccc(OC)cc1)COCC2

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
UGCG Q16739 7/20 0.40
TNKS2 Q9H2K2 6/20 0.40
WNT3A P56704 1/20 0.40
IDO1 P14902 1/20 0.40
TDO2 P48775 1/20 0.40
TNKS O95271 5/20 0.39
ALDH1A1 P00352 2/20 0.37
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
CYP2D6 P10635 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35
HTR3A P46098 1/20 0.34
PARP1 P09874 3/20 0.34
PARP2 Q9UGN5 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21836666 0.75 UGCG (0.44) UGCGTNKS2WNT3ATNKSALDH1A1
SCHEMBL29445725 0.70 ATM (0.45) IDO1TDO2ALDH1A1CYP2D6CYP1A2
SCHEMBL24288695 0.69 ESR1 (0.33) IDO1TDO2SLC6A2SLC6A4SLC6A3
SCHEMBL21191877 0.68 IDO1 (0.41) IDO1TDO2ALDH1A1CYP2D6CYP1A2
SCHEMBL25416376 0.66 PDE4D (0.50) UGCGTNKS2TNKSALDH1A1CYP2C19
SCHEMBL21836673 0.65 F12 (0.31)
SCHEMBL25567711 0.64 SMN1; SMN2 (0.44) UGCGTNKS2WNT3AALDH1A1
SCHEMBL120187 0.62 CA12 (0.58) ALDH1A1CYP2D6CYP1A2CYP2C19
SCHEMBL24289267 0.62 ALDH1A1 (0.37) TNKS2WNT3AALDH1A1
SCHEMBL21836693 0.61 MTOR (0.31) TNKS2WNT3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11597725-B2 URAT1 inhibitor for promoting uric acid excretion JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2023-03-07 US disclosed
CN-108484600-B URAT1 inhibitors for promoting uric acid excretion 江苏新元素医药科技有限公司 2022-12-13 CN disclosed
EP-3632904-B1 URAT1 INHIBITORS FOR PROMOTING URIC ACID EXCRETION JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) 2022-04-20 EP disclosed
EP-3632904-B1 URAT1 INHIBITORS FOR PROMOTING URIC ACID EXCRETION JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) 2022-04-20 EP disclosed
US-20200262832-A1 URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2020-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11597725-B2 URAT1 inhibitor for promoting uric acid excretion SLC10A6, SLC10A1, SLC28A1 UGCG 278/4885TNKS2 3623/4885WNT3A 3593/4885
US-20200262832-A1 URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION SLC10A6, SLC10A1, SLC28A1 UGCG 278/4885TNKS2 3623/4885WNT3A 3593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.